Drug Profile
Research programme: targeted gene therapy - PhageNova Bio
Alternative Names: RGD AAVP TNFLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator AAVP Biosystems
- Developer PhageNova Bio
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Tumour necrosis factor alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer